InnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of ICP-488, a treatment designed for individuals with moderate to severe plaque psoriasis.
This marks a significant milestone in the development of the drug, which is a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The randomised, multi-centre, double-blind, placebo-controlled trial aims to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients.
A total of 129 moderate to severe plaque psoriasis patients were enrolled in the study.
Participants in the trial were randomly assigned to one of three groups in equal proportions to receive either a 6mg or 9mg once-daily ICP-488 or a placebo.
They will undergo treatment for 12 consecutive weeks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataICP-488 has previously shown promising efficacy and safety results in a Phase I trial for treating psoriasis.
InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “Psoriasis requires long-term management, and there is still a significant unmet demand for new drugs, especially oral medications in its treatment.
“We are very pleased to see the completion of patient enrollment in the phase II clinical trial for the treatment of psoriasis with ICP-488. We remain committed to diligently advancing the clinical development of this promising therapy, with the goal of providing improved treatment options to psoriasis patients as soon as possible.”
In March, the company dosed the first patient in a Phase Ib trial to investigate the combination of ICP-189 and ArriVent BioPharma’s furmonertinib in treating non-small cell lung cancer.
